Clinical Trials Logo

Clinical Trial Summary

Observational study investigating the relationship between tumour amphiregulin, epiregulin and epithelial growth factor receptor expression and response to anti-EGFR agents in advanced colorectal cancer.


Clinical Trial Description

Background: The anti-EGFR agents, cetuximab and panitumumab are approved by NICE for the first-line treatment of patients with RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC). However RAS-wt status is not sufficient to guarantee anti-EGFR benefit. Differential tumour expression of the EGFR ligands, amphiregulin (AREG) and epiregulin (EREG), as well as the EGFR receptor itself, are putative predictive biomarkers for response to anti-EGFR agents and may therefore help better identify patients who will benefit from treatment. Objectives: This study aims to assess the utility of tumour AREG, EREG and/or EGFR expression, alone or in combination, as predictive biomarkers for response to anti-EGFR agents in aCRC. The investigators will develop a scoring system and categorical cut off points to differentiate AREG/EREG/EGFR positive and negative cases and correlate these with response to therapy as assessed by: Primary endpoint: Progression Free Survival (PFS) Secondary endpoints: Overall Survival (OS), Objective Response Rate (ORR), Disease Control Rate (DCR) Finally, the investigators will utilise digital pathology and artificial intelligence (AI) technologies to automate as far as possible the process of evaluating AREG/EREG/EGFR status. During the study, the investigators will monitor the costs of implementing the test and time taken to derive test results in order to facilitate cost-effectiveness calculations and assess the feasibility of delivering the test in future routine clinical practice. Study Design: A multicentre UK observational cohort study (retrospective and prospectively recruited cohorts). Study population: Patients with RAS-wt aCRC who received or are receiving standard care palliative treatment with an anti-EGFR agent and chemotherapy of physician's choice. Within the retrospective cohort, patients who received single agent anti-EGFR therapy under previous Cancer Drugs Fund criteria will be accepted. Key Inclusion Criteria: - Biopsy proven advanced colorectal adenocarcinoma at time treatment commenced (either inoperable metastatic disease at diagnosis or inoperable recurrent disease) - Aged 18 or over at time treatment commenced - The patient has received or has consented to receive treatment with cetuximab or panitumumab Key Exclusion Criteria: - Stage I, II or III colorectal adenocarcinoma - RAS mutant disease - Eligible for potentially curative surgery (prospective cohort) - Underwent cancer surgery subsequent to anti-EGFR therapy (retrospective cohort) - Unable to provide informed consent (with the exception of patients in the retrospective cohort who have passed away) Procedures: The study is observational and does not involve participants undergoing any study-specific investigations or treatments. Results of routine investigations and outcomes from standard care with an anti-EGFR agent will be collected from medical notes and, for the prospective cohort, during routine clinic appointments. Date of death will also be recorded. Initial and follow-up radiological and clinical assessments will occur as per local standard practice. Previously obtained pathological specimens will be retrieved for immunohistochemical analysis of tumour AREG, EREG and EGFR expression. Treatment During Study: This study will observe outcomes from standard first line palliative treatment of RAS-wt aCRC. In line with current NICE guidelines, such treatment will involve physician's choice of panitumumab or cetuximab in combination with: - 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) or - 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) Where RAS mutation status is only available after commencement of treatment and the anti-EGFR agent is therefore commenced in cycle two, patients may still be recruited to the study. It is anticipated that most patients in the retrospective cohort will have received current standard first line palliative treatment of RAS-wt aCRC as above. However, patients who were treated with single agent anti-EGFR therapy under previous Cancer Drugs Fund criteria may still be recruited. Statistical Methods: Sample size: Data from 480 patients will be collected for the retrospective cohort and 480 patients will be recruited to the prospective cohort. Primary endpoint analysis: PFS will be calculated from date of commencing treatment to date of progression or death from any cause (whichever is sooner). Time of progression will be determined clinically or radiologically by the participant's treating oncologist. Where the anti-EGFR agent was commenced in cycle 2, the definition of the start of treatment will remain cycle 1 day 1 of palliative chemotherapy. Key secondary endpoint analyses: OS will be determined from date of commencing treatment to death. ORR is the proportion of patients with documented radiological complete or partial response on first follow-up imaging whereas DCR is the proportion of patients with either radiologically stable disease or a response. For the purpose of these analyses, those without follow-up imaging will be assumed to have progressed. AREG/EREG/EGFR expression will be assessed as a continuous variable and using dichotomous classifiers ('high' and 'low') for each marker individually and in combination. Subgroup analyses will be performed for BRAF mutation positive tumours, primary tumour location (right versus left colon, and rectum) and previous surgery (primary excised versus in situ). Within the retrospective cohort, those who received single agent anti-EGFR therapy under previous Cancer Drugs Fund criteria will be analysed separately. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03986541
Study type Observational
Source University of Leeds
Contact
Status Completed
Phase
Start date September 23, 2019
Completion date July 22, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03594448 - Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
Completed NCT01570452 - Matrilysin Expression in Different Stages of Colorectal Tumors N/A
Recruiting NCT05354817 - Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin Phase 2
Recruiting NCT05576896 - Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory Phase 2
Completed NCT04715061 - Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments N/A
Terminated NCT03149679 - The p53 Colorectal Cancer Trial Phase 2
Completed NCT05550701 - Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
Enrolling by invitation NCT04149613 - Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
Completed NCT04425239 - Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer Phase 2
Completed NCT06329700 - Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
Recruiting NCT05382741 - Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial Phase 2
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Not yet recruiting NCT04917276 - Treatment Response Prediction System of mCRC Patients Based on CTC
Not yet recruiting NCT06296056 - Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care Phase 1
Recruiting NCT04714814 - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Not yet recruiting NCT05451719 - Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy Phase 2
Completed NCT03031444 - Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis Phase 2/Phase 3
Completed NCT05164419 - Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
Recruiting NCT05171660 - Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer Phase 3
Recruiting NCT05426005 - Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer Phase 1/Phase 2